卡那努马布
医学
炎症
阿司匹林
心肌梗塞
冠状动脉疾病
发病机制
疾病
血栓形成
内科学
免疫学
心脏病学
阿纳基纳
摘要
Inflammation is widely believed to play a central role in the pathogenesis of atherosclerosis and acute coronary events.1,2 Although treatments with proven benefits for secondary prevention of coronary artery disease (e.g., statins and aspirin) appear to have salutary effects on inflammation, the identification of an effective treatment specifically targeting inflammation has been elusive.3 The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) provided encouragement that targeting inflammation may be an effective treatment in chronic coronary artery disease. In CANTOS, canakinumab, a monoclonal antibody inhibiting interleukin-1β, reduced the level of high-sensitivity C-reactive protein and resulted in a modestly lower risk of the composite . . .
科研通智能强力驱动
Strongly Powered by AbleSci AI